肺癌SABR的MLC追踪可行高效且靶区剂量精准正常组织剂量更低
该首次人体试验纳入17例1期非小细胞肺癌或肺转移患者,采用电磁信标引导MLC追踪行SABR,并与基于4DCT的ITV对照计划比较。MLC追踪治疗可行且高效,平均治疗时间8分钟,16/17例追踪PTV小于ITV计划PTV,平均肺剂量和V20Gy显著降低,重建GTV D98%较ITV计划显著改善。
要点
- 17例肺癌SABR患者全部成功完成MLC追踪治疗,共70个成功分次
- MLC追踪平均治疗时间8分钟,从CBCT开始至治疗结束平均22分钟
- 16/17例追踪PTV较ITV计划缩小,肺平均剂量和V20Gy显著降低
核心结论
- 肺癌SABR的MLC追踪可行、高效,能实现高精度靶区剂量并降低正常组织剂量。
研究设计与样本
- 首次人体试验纳入17例1期NSCLC或肺转移患者,行电磁信标引导MLC追踪SABR(NCT02514512)。
- 追踪计划PTV为呼气末GTV外扩5 mm,对照计划PTV为4DCT-derived ITV外扩5 mm。
主要发现
- 17例患者全部成功治疗,共70个成功分次。
- MLC追踪平均治疗时间8分钟,CBCT开始至治疗结束平均22分钟。
- 16/17例追踪PTV小于ITV计划PTV,缩小范围1.6%至44%(或0.6至18 cc)。
- 平均肺剂量降低27 cGy、V20Gy降低50 cc,差异有统计学意义(p<0.02)。
- 重建GTV D98%较ITV计划显著改善(p<0.05)。
关键数值与推荐
- 追踪PTV为呼气末GTV外扩5 mm,对照PTV为4DCT-derived ITV外扩5 mm。
- 平均肺剂量降低27 cGy、V20Gy降低50 cc(p<0.02)。
- GTV D98%改善有统计学意义(p<0.05)。
临床怎么用
- 对适合的肺癌SABR患者,可考虑电磁信标引导MLC追踪以减少PTV和正常组织剂量。
- 治疗流程可在约22分钟内完成,具备临床可操作性。
局限性
- 首次人体试验样本量有限(17例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions. METHODS AND MATERIALS: Seventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder-guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PTV expanded 5 mm from a 4DCT-derived internal target volume (ITV). Treatment was delivered using a standard linear accelerator to continuously adapt the MLC based on transponder motion. Treated volumes and reconstructed delivered dose were compared between MLC tracking and comparator ITV-based treatment. RESULTS: All seventeen patients were successfully treated with MLC tracking (70 successful fractions). MLC tracking treatment delivery time averaged 8 minutes. The time from the start of CBCT to the end of treatment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was smaller than the ITV-based PTV (range -1.6% to 44% reduction, or -0.6 to 18 cc). Reductions in mean lung dose (27 cGy) and V20Gy (50 cc) were statistically significant (p < 0.02). Reconstruction of treatment doses confirmed a statistically significant improvement in delivered GTV D98% (p < 0.05) from planned dose compared with the ITV-based plans. CONCLUSION: The first treatments with lung MLC tracking have been successfully performed in seventeen SABR patients. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose.
引用
- Booth J, Caillet V, Briggs A, et al. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose. Radiother Oncol. 2020. PMID: 33152399. doi:10.1016/j.radonc.2020.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。